Clinical Trial Search

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Progression Free Survival (PFS) — 11 months

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: Pharmacokinetics Measured as Area Under Curve (AUC[0-12h]) — 35.5; 5.7 mg*hour/Liter

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events (IMAEs) — 4.1; 0; 0; 0 Percentage of participants

Primary: Response Rate — 8 Participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001

Primary: Objective Response Rate (ORR) — 36.4; 26.7 Percentage of Participants

Primary: Metabolic Response — 5 participants

Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months

Primary: Recommended Dose for Phase 2 Studies of LY573636-Sodium Combined With Sunitinib in Participants With Metastatic Renal Cell Carcinoma — NA; NA; NA; NA micrograms per…

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Progression-free Survival — 12 Weeks

Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081

Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs

Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants

Primary: Follow-up Duration — 1.07 years

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants